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Abstract.  Application of TGF~I  (10-100 ng) to the 
chicken chorioallantoic membrane (CAM) for 72 h 
resulted in a dose-dependent, gross angiogenic re- 
sponse.  The vascular effects induced by TGF~I  were 
qualitatively different than those induced by maximal 
doses of basic FGF (bFGF) (500 ng).  While TGF~ 
induced the formation of large blood vessels by 72 h, 
bFGF induced primarily small blood vessels. Histo- 
logic analysis revealed that TGF/31 stimulated 
pleiotropic cellular responses in the CAM.  Increases 
in fibroblast and epithelial cell density in the area of 
TGF~I  delivery were observed as early as 4 h after 
TGF~I  treatment.  By 8 h,  these cell types also 
demonstrated altered morphology and marked inhibi- 
tion of proliferation as evidenced by 3H-thymidine 
labeling.  Thus,  the TGF~l-stimulated accumulation of 
these cell types was the result of cellular chemotaxis 
from peripheral areas into the area of TGF/31 delivery. 
Microscopic angiogenesis in the form of capillary 
sprouts and increased endothelial cell density first be- 
came evident at 16 h.  By 24 h,  capillary cords ap- 
peared within the mesenchyme of the CAM, extending 
towards the point of TGF~  delivery. 3H-thymidine 
labeling revealed that the growth of these capillary 
cords was due to endothelial  cell proliferation.  Finally, 
perivascular mononuclear inflammation  did not be- 
come evident until 48 h of treatment,  and its presence 
correlated spatially and temporally with the gross and 
histological remodelling of newly formed capillary 
cords into larger blood vessels. In summary, these 
data suggest that,  in the chicken CAM, TGFffl initi- 
ates a  sequence of cellular responses that results in 
growth inhibition,  cellular accumulation through 
migration,  and microvascular angiogenesis. 
T 
RAr~SFOI~r~ING growth factor beta (TGF/3)  ~  was orig- 
inally identified by its ability to induce the reversible 
transformation of nonneoplastic cells in culture (Moses 
et al.,  1981; Roberts et al.,  1981). Thus,  it was  initially 
implicated  to have a role in the process of neoplastic  trans- 
formation.  Subsequently,  however, TGF/3 was identified  in 
many normal tissues (Proper et al.,  1982;  Roberts et al., 
1982), additional  TGF/3 biologic activities  were discovered 
(reviewed in Moses et al., 1988), and several growth factors 
closely related to TGF/3 were identified  (TGF~I,  TGF~2, 
and TGF/33; reviewed in Lyons and Moses, 1990). Our con- 
cepts of the roles of TGF/3 in vivo have therefore  evolved. 
The growth factors comprising the TGF~ family  are now 
thought to have roles in embryological development and nor- 
mal physiology,  as well as in pathophysiology. 
Our best understanding  of TGF/3 function  in  vivo is  in 
wound healing.  TGF~ is stored in platelets  (Childs  et al., 
1982) and released from platelets during degranulation  (As- 
soian and Sporn, 1986). TGF~ is also produced by cultured 
1. Abbreviations used in thispaper: bFGF, basic FGF; CAM, chicken cho- 
rioallantoic membrane assay;  PMN, polymorphonuclear cell; SEC,  sub- 
epithelial capillary network; TGF~, transforming growth  factor beta. 
T-cells  (Kehrl  et al.,  1986),  macrophages (Assoian  et al., 
1987), monocytes (Assoian et al.,  1987), neutrophils  (Gro- 
tendorst et al.,  1989), and fibroblasts  (Tucker et al.,  1983; 
Pircher et al.,  1984). These cell types have important,  in- 
tegrated functions in wound healing, and hence it is not sur- 
prising that TGF/3 is a biologically significant component of 
wound fluid derived from subcutaneous wound chambers 
(Cromack et al., 1987; Grotendorst et al.,  1988). Addition- 
ally, in vivo administration  of TGF/31, the prototypic TGF/3, 
yields a wound healing  response. When TGF~'I is injected 
subcutaneously into newborn mice a granulation  tissue re- 
sponse characterized by inflammation,  fibrosis,  and angio- 
genesis is observed (Roberts et al., 1986). TGF/31 can stimu- 
late increased tensile strength of incisional  wounds (Mustoe 
et al.,  1987) and reverse the wound healing deficits induced 
by glucocorticoids (Pierce et al.,  1989a)  and adriamycin 
(Lawrence et al.,  1985). Thus, although  the specific inhibi- 
tion of endogenous TGF/3 has not yet been shown to impair 
normal wound healing, TGF~ is most likely a natural media- 
tor of wound healing. 
To  understand  the mechanisms  by which  TGF/~ might 
function in wound healing and other processes, the effects of 
TGF/3 have been studied on isolated cells  in vitro.  These 
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The Journal of Cell Biology, Volume I 11, August 1990 731-741  731 Figure L  CAM vascular reactions to TGF/~I and bFGE A control methylcellulose disk (A) and methylcellulose disks impregnated with 
either 50 ng TGF#I (B and D) or 500 ng bFGF (C) were placed onto the CAM for 72 h (A-C) or 24 h (D). TGF/~I induced a marked 
angiogenic response after 72 h (B) as compared to the control (A). Relative to the small blood vessels induced by bFGF at 72 h (arrowhead, 
C), TGF/~I  consistently induced the formation of much larger blood vessels. This was the result of vascular remodeling since much smaller 
blood vessels were induced by TGF/$1 after only 24 h (arrowhead, D). Bars,  1 mm. 
studies have demonstrated that many of the tissueresponses 
associated with in vivo TGF#I administration result from the 
direct action of TGF/$1 on specific cell types (reviewed in 
Roberts et al.,  1988; Lyons and Moses,  1990).  However, in 
vitro studies  on endothelial  cells have not yielded a  clear 
understanding  of the mechanisms by which TGF/~ induces 
angiogenesis.  The direct effects of TGF/$1 on cultured  en- 
dothelial cells are perplexing, perhaps because the many in 
vitro endothelial cell assays model different aspects of angio- 
genesis. In vitro assays that measure the morphologic reor- 
ganization of individual endothelial ceils into capillary tubes 
(in vitro angiogenesis) model the later stages of angiogenesis 
when loosely connected capillary endothelial cells differenti- 
ate from a proliferative, migratory phenotype into a quies- 
cent, vascular epithelium phenotype (Wagner, 1980). TGFffl 
is stimulatory to this process. When endothelial ceils are dis- 
persed in three-dimensional collagen gels, TGF~I stimulates 
their morphologic reorganization into capillary tube struc- 
tures and stimulates cell-mediated contraction of the colla- 
gen gel (Madri et al.,  1988). This suggests that TGF/~I may 
be important in directly stimulating the resolution of angio- 
genesis or in maintaining the differentiated state of endothe- 
lial cells. 
In vitro endothelial  cell assays that measure endothelial 
cell protease production,  invasion, migration, or prolifera- 
tion model early events in angiogenesis (Folkman,  1985). 
TGF/$1  is  inhibitory  in  these  assays.  TGF/$1 inhibits  en- 
dothelial cell production of plasminogen activator (Saksela 
et al., 1987), and correspondingly, it inhibits endothelial cell 
invasion  of human  amniotic  membranes  (Mignatti  et  al., 
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Figure 2. Dose-responsive ef- 
fect  of TGFBI  on  mean an- 
giogenic scores.  Control  me- 
thylcellulose disks (Cntl) and 
methylcellulose disks impreg- 
nated  with  either  10,  50,  or 
100 ng of'l'GF/~l were applied 
to the CAM for 72 h. Vascular 
responses for each disk were 
then scored on a 0--4+  scale 
based on the criteria described 
in  Materials  and  Methods. 
Each  value  is  the  mean  + 
SEM, n/> 16. (*) P< 0.001 as 
compared to control. 
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and proliferation (Miiller et al., 1987); even submaximal in- 
hibitory doses cannot be overcome by the endothelial cell 
mitogens acidic or basic FGF (bFGF) (Frater-Schroder et 
al., 1986; Baird and Durkin, 1986). Furthermore, when en- 
dothelial cells are plated on the surface of collagen gels, 
TGF/31 inhibits PMA-induced endothelial cell invasion and 
subsequent capillary tube formation (Mfiller et al.,  1987). 
Taken  collectively, the  direct  effects  of TGF/31 on  en- 
dothelial cells in vitro might suggest that TGF/31 is a general 
repressor of angiogenesis. Yet, administration of TGF/31 in 
vivo yields endothelial cell growth and the formation of new 
capillaries, a definitive angiogenic response (Roberts et al., 
1986). To reconcile these paradoxical observations, we have 
used the chicken chorioallantoic membrane (CAM) assay to 
examine the temporal and spatial sequence of cellular re- 
sponses that occurs during TGF/31-induced angiogenesis. 
Materials and Methods 
Embryos and Reagents 
Fertilized white leghorn chicken eggs were obtained from Truslow Farms 
(Chestertown, MD).  Porcine TGF~I  was obtained from R&D  Systems 
(Minneapolis, MN). Recombinant human bFGF was the kind gift of Dr. 
Lawrence Coussens of Chiron Corporation (Emeryville, CA). 
CAM Assay 
The methods used for egg incubation have been described (Auerbach et al., 
1974).  Methylcellulose disks were prepared through the dehydration of 
methylcellulose solutions on teflon rods as described (Taylor and Folkman, 
1982).  Porcine TGF~I was dissolved in filter-sterilized 4 mM HC1, 0.5% 
BSA at a concentration of 10 ng/mi. Recombinant human bFGF was dis- 
solved in filter-sterilized 10 mM Tris-HCl, 1 mM EDTA, pH 7.4, at a con- 
centration of 0.5  mg/mi.  Growth factors, BSA (used as a  carrier),  and 
deionized water were added to 1% methyiceUulose to yield the appropriate 
concentration of growth factor in 0.5% methylcellulose, 1.25 mg/ml BSA. 
All solutions were sterile. FOr control disks the hydration buffer without 
growth factor was added. 
Methylcellulose disks were placed onto the CAMs on day 9 of incubation 
and after 3 d the angiogenic responses to each disk were scored without 
knowing their growth factor composition. Scores were based on a 0-4+ re- 
sponse scale as previously described ('v~ et al., 1985).  After all disks were 
scored, their compositions were revealed, and the mean angiogenic score 
for each treatment was compared to the mean score for the control disks 
using the two-tailed t test. 
Histology an'd  Autoradiography 
After scoring, CAMs were flooded with Bonin's fixative in situ and addi- 
tional fixative was injected into the allantoic sac. Tissue samples were re- 
moved from the CAM,  dehydrated through  alcohol,  and  embedded in 
paraffin wax. 10-#m sections were mounted on slides and stained with he- 
matoxylin and eosin. Morphologic criteria were used to identify specific 
cell types. Endothelial cells were identified by their localization surround- 
ing vascular lumens and their flat, epithelial appearance. Inflammatory cells 
were  identified through  their distinctive granular  cytoplasm (polymor- 
phonuclear cells) or enlarged size (mononuclear cells) (Lucas,  1974). 
FOr autoradiography,  20 t~l of 3H-thymidine,  1.0 mCi/ml (~80 Ci/mmol; 
New England Nuclear, Boston, MA) in PBS, was pipetted onto each meth- 
ylcellulose disk and the surrounding areas.  After a  4-h incubation, the 
CAMs were carefully overlaid with Bouin's fixative and prepared for histol- 
ogy as described above. 10-/zm sections were deparaffinized and then coated 
with 1:I water-diluted Ilford K-5 emulsion (Polysciences, Inc., Warrington, 
PA) for autoradiography. At the appropriate times, slides were developed 
in 1.6% Kodak D-19 developer and fixed in 30% sodium thiosulfate. The 
sections were then counterstained with tolnidine blue. 
To calculate endothelial cell labeling indices, representative autoradiog- 
raphy sections from control or TGF/31-tmated CAM tissue samples were ex- 
amined for total endothelial cell numbers and total ~H-thymidine labeled 
endothelial cells. Over 100 endothelial cells were examined per tissue sam- 
ple. The resultant endothelial cell labeling indices were statistically ana- 
lyzed using the two-tailed t test. 
Morphometric and Cell Density Measurements 
Multiple CAM tissue samples of a given time point were fixed and embed- 
ded. From each tissue sample serial sections were made, representative sec- 
tions were chosen, and the sections were analyzed using a computerized 
morphometric analysis program (Southern Micro Instruments, Inc., At- 
lanta, GA). 
To calculate mean CAM thickness, all of  the representative sections from 
a particular tissue sample were measured for maximal thickness and aver- 
aged to yield a mean CAM thickness for that tissue sample. The mean CAM 
thickness measurements for all of the tissue samples of a given time point 
were then averaged to yield a  mean CAM thickness for that time point. 
For calculating fibroblast and endothelial cell densities, areas of known 
size excluding blood vessels larger than 50 #m were demarcated. All of the 
fibroblasts and endothelial cells within the demarcated areas were counted 
and cell densities calculated. The cell densities from the representative sec- 
tions of each tissue sample were averaged to yield the mean cell densities 
for each tissue sample. Then, the mean cell densities for all tissue samples 
of a given time point were averaged to yield the mean cell densities for each 
time point. A similar analysis was utilized for calculating mean epithelial 
cell densities, except that densities were calculated per unit length of the 
CAM instead of per unit area. 
Resuits 
Gross Vascular  Effects Induced by TGFf31 
To examine the effects of TGF~I on the CAM vasculature 
TGF/~l-impregnated methylcellulose  disks were used as a lo- 
cal delivery system. This system has been used previously 
for the delivery of bFGE protamine, heparin, and steroids 
to the CAM (Shing et al., 1985; Taylor and Folkman, 1982; 
Folkman et ai., 1983). Application of a control methylcellu- 
lose disk to the CAM for 72 h resulted in little or no change 
in the normal blood vessel pattern (Fig. 1 a). However, appli- 
cation of a TGF/31-impregnated methylcellulose  disk (50 ng) 
for the same period of time resulted in a marked angiogenic 
effect (Fig. 1 b). TGF/31 stimulated an increase in the density 
of arterioles and venules arranged in a radial pattern around 
the disk. 
The angiogenic effects were scored on a 0-4+ scale based 
on the morphologic appearance of the vascular responses 
(see Materials and Methods for scoring system). Application 
of 10, 50, or 100 ng of TGF/31 to the CAM resulted in a dose 
responsive increase in the mean angiogenic score (Fig. 2). 
All three doses resulted in a significantly higher mean score 
over control disks (P <  0.001, two-tailed t test). 
Since the CAM assay has been Used extensively for the 
testing of bFGF-induced angiogenesis (Gospodarowicz et 
al.,  1985;  Shing et al.,  1985),  we compared the vascular 
effects induced by bFGF with those of TGF/31. A maximally 
effective dose of bFGF (500 ng or higher) induced angio- 
genic effects that were qualitatively different than the effects 
induced by TGF/31. After 72 h,  when the vascular effects 
were greatest, bFGF induced the growth of very small blood 
vessels (Fig. 1 c), as compared to the larger vessels induced 
by TGF/31 (Fig.  1 b).  Because the mechanism of TGF/31- 
induced angiogenesis could be through the production of 
bFGF, we examined TGF/31-treated CAMs at earlier times to 
determine if the vascular changes were similar to those in- 
duced by bFGE Angiogenesis was first grossly discerned at 
24 h after TGF/31 administration (Fig. 1 d). Although small 
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The Journal of Cell Biology, Volume I 11,  1990  734 Figure 3. Histologic effects induced by TGFfll at various times after treatment. (A) Control-treated CAMs harvested at 72 h demonstrated 
thin chorionic and allantoic epithelia (ce and ae), sparse fibroblasts, and an SEC (sec) juxtaposed to the chorionic epithelium. Occasional 
PMNs (closed arrowheads) were observed. (B) CAMs treated with TGFfll (50 ng) for 8 h demonstrated fibroblast (.tb) accumulation be- 
tween the SEC and the chorionic epithelium, allantoic epithelial thickening, and accumulated sloughed ceils on the surface of the chorionic 
epithelium. (C) After 8 h of'IX]Fill treatment, the allantoic epithelium demonstrated thickening due to cellular hypertrophy and acquisition 
of columnar morphology. (D) Increased numbers of capillaries were first visible at 16 h in the SEC and in the mesenchyme of the CAM. 
(E, higher magnification of D) Occasionally capillary sprouts (cs) were observed. (F) At 24 h, both chorionic and allantoic epithelial 
stratification were apparent. (G) Also at 24 h, endothelial cells were observed to invade the fibroblasts that had accumulated above the 
SEC, forming a granulation-like tissue (compare to Fig. 4 d). (H) Furthermore, fibroblasts as well as capillary cords (arrows) demonstrated 
radial organization relative to the point of TGFfll delivery. (I) At 72 h, mononuclear infiltration was evident (open arrowheads) in a peri- 
vascular distribution (by, blood vessel). Representative sections (10 #m) were stained with hematoxylin and eosin. Bars: (A-D, F-I) 50 
~m;  (E) 20 #m. 
blood vessels were apparent, they converged upon a central, 
opaque area which, as shown below, corresponded to an area 
of increased fibroblast density and epithelial thickening. Be- 
tween 24 and 72 h the TGFfll-induced angiogenesis appeared 
to remodel from very fine blood vessels to larger vessels 
(compare Fig. 1, b and d). Neither the central opacity visual- 
ized at 24 h, nor the apparent vascular remodeling between 
24 and 72 h  were observed after bFGF administration. 
Microscopic Effects Induced by TGF{31 
The progression of TGF/~l-induced angiogenesis was  then 
examined histologically.  Serial  cross  sections  were made 
through samples of CAMs treated with TGF/~I  (50 ng) for 
varying times, and central sections were examined for cellu- 
lar responses. Consistent with the gross observations, 72-h 
control-treated CAMs  were of uniform thickness both be- 
neath the methylcellulose disk and in the peripheral regions. 
From 0 to 72 h, the histologic appearance of control-treated 
CAMs was exactly the same. CAMs that had been treated 
with control methylcellulose disks for 72 h (Fig. 3 a) demon- 
strated a thin chorionic epithelium, a very fine subepithelial 
capillary network (SEC) just  under the  chorionic epithe- 
lium, a mesenchymal layer consisting of sparse fibroblasts 
and occasional blood vessels, and a very thin aUantoic epi- 
thelium.  The control methylcellulose disks  did  not cause 
wounding or inflammation. 
In contrast, application of TGF/31-impregnated methylcel- 
lulose disks  (50 ng) to the CAM resulted in alterations in 
fibroblast, epithelial, and endothelial cell morphology. After 
an 8-h exposure to TGFfll, fibroblasts beneath the SEC ap- 
peared to accumulate to a higher density, and they demon- 
strated a distinctive bipolar morphology with vertical align- 
ment relative to the plane of the CAM (Fig. 3 b). Fibroblasts 
were also observed to accumulate above the SEC, aligning 
parallel to the plane of the CAM  and forcing the SEC to 
move downwards (Fig. 3 b; compare Fig. 3, d and a). The 
fibroblasts beneath the SEC expressed increased amounts of 
fibrillar, extracellular matrix-like material which was proba- 
bly composed partially of collagen since these fbrils stained 
positive with Masson-Trichrome stain (data not shown). Both 
allantoic and chorionic epithelial thickening were also ob- 
served by 8 h. The chorionic epithelium thickened via strat- 
ification (Fig. 3 d), and the aUantoic epithelium thickened 
primarily via cellular hypertrophy and the acquisition of co- 
lumnar morphology (Fig. 3 c). These epithelial effects were 
not always apparent in the same sections since they were not 
always parasagittal. Polymorphonuclear cell (PMN) inflam- 
mation was evident by 8 h, but the distribution of these cells 
was fairly restricted to the peripheral regions.  Within the 
centrally affected areas few inflammatory cells were noted. 
An accumulation of necrotic cells was usually observed be- 
tween the TGFfll-impregnated methylcellulose disk and the 
allantoic epithelium (e.g.,  Fig.  3  b).  These necrotic ceils 
were primarily composed of sloughed chorionic epithelial 
cells, but RBCs and PMNs could also be found. 
Increased numbers  of capillaries  were first apparent at 
"~16 h after TGF/~I treatment. Capillaries within the SEC ap- 
peared to be more numerous and more densely packed at this 
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Figure 4. Effects  of TGFBI on CAM cell densities. (A) Fibroblast; 
(B) aUantoic epithelial cell; and (C) endothelial cell densities were 
measured at various times after TGFB1 (50 rig) treatment. Each 
point represents the mean cell density + SEM of at least three tis- 
sue samples. Fibroblast and endothelial cell densities are expressed 
per unit area, whereas allantoic epithelial cell density is expressed 
per unit length of  the CAM. See Materials and Methods for detailed 
description of cell density calculations. 
time (Fig. 3 d). Small blood vessels beneath the SEC also 
appeared more numerous, and they revealed occasional cap- 
illary sprouts extending towards the SEC (Fig. 3 e). Neither 
mononuclear nor PMN inflammatory cells were associated 
with these capillary sprouts. 
Over the course of 24 h the area of TGFBl-induced effects 
enlarged and earlier responses were amplified. 24-h TGFB1- 
treated CAMs were ~4-fold thicker as compared to controls 
(P <  0.0001, n  =  8, two-tailed t test) and demonstrated an 
enlarged area of epithelial and fibroblastic effects. Both the 
ailantoic and chorionic epithelia became markedly stratified 
(Fig. 3f). Much of the fibroblast accumulation seen beneath 
the SEC at 8 h had diminished by 24 h (compare fibroblast 
densities in Fig. 3, h and b). However, fibroblasts continued 
to accumulate above the SEC at the mesenchymal/epithelial 
boundary (Fig. 3f), and endothelial cells lining small capil- 
laries were also seen to invade this space forming a granula- 
tion-like tissue (Fig. 3 g). The central location of the epithe- 
lial cell stratification and fibroblast accumulation probably 
accounts for the grossly opaque appearance of the CAM at 
24 h (e.g., Fig.  1 d). 
At 24 h, fibroblasts beneath the SEC were aligned radially 
relative to the point of TGFB1 delivery (Fig. 3f). This radial 
pattern  was  reiterated  in  the  developing  capillary  cords 
which extended from larger blood vessels towards the point 
of TGFBI delivery (Fig. 3,fand h). While a few of these cap- 
illary cords traversed the full distance between the larger 
blood vessels and the SEC (e.g., Fig. 3 f), most appeared 
incomplete and lacked connection with the SEC (Fig. 3 h). 
This was determined by examining serial sections in many 
different TGFfll-treated CAM tissue samples. Inflammatory 
cells were not associated with these capillary cords. 
From 24 to 72 h the fibroblast and epithelial hypercellular- 
ity receded, yet the gross and histologic angiogenesis per- 
sisted. By 48 h the CAM appeared to become thinner and 
fewer fibroblasts were  apparent.  Significant mononuclear 
inflammation was first noted at this time, particularly near 
blood vessels (data not shown). At 72 h, fibroblast numbers 
were diminished and mononuclear cell inflammation con- 
tinued to accumulate (Fig. 3 i), yet focal concentrations of 
large blood vessels were clearly evident (Fig. 3 i). Since the 
gross angiogenic effect stimulated by TGF/31 was observed 
to remodel from small vessels to larger vessels between 24 
and 72 h  (Fig.  1,  d  and b),  the corresponding histologic 
changes in blood vessel size and numbers compare well (Fig. 
3, fand i). 
Effect of TGFI31 on Cell Density 
TGFB1 has been shown to affect both cellular chemotaxis 
and proliferation. To separate the effects of TGFB1 on these 
two processes in the CAM, the changes in cellular density 
and 3H-thymidine incorporation after TGF/31 treatment were 
examined. As mentioned previously, from 0 to 72 h control- 
treated CAMs did not demonstrate any changes in gross or 
histological appearance. The fibroblast, epithelial cell, and 
endothelial cell densities in control-treated CAM's were con- 
stunt during this period of  time. Initial observations suggested 
that two populations of fibroblasts developed after TGFB1 
(50 rig) treatment. Fibroblasts above the SEC at the mesen- 
chymal/epithelial border appeared to accumulate to the high- 
est density (e.g., Fig. 3 g), whereas fibroblasts beneath the 
SEC appeared to accumulate only transiently at ~8 h after 
TGFB1 treatment (e.g., Fig. 3 b). Due to the difficulty  in dis- 
tinguishing fibroblasts from endothelial cells above the SEC, 
only fibroblasts beneath the SEC and in the central area of 
TGFB1 effect were counted. The density of this population 
of fibroblasts increased ~3.5-fold during the first 4 h of TGF/31 
treatment, then slowly decreased over 48 h to control levels 
(Fig. 4 a). Within the centrally affected area, the density of 
allantoic epithelial cells reached a plateau level rv3_fold higher 
than controls at 8 h of  treatment (Fig. 4 b). Although the den- 
sity of allantoic epithelial cells remained elevated at 48 h, by 
72 h it was very close to control levels (e.g., Fig. 3 i). 
Endothelial cells demonstrated a different temporal pat- 
tern of density regulation (Fig. 4 c). Only endothelial cells 
lining small blood vessels (<50 #m diameter) and capillaries 
beneath the SEC were included in density measurements 
since endothelial cells within the  SEC could not be ade- 
quately differentiated from fibroblasts.  While the densities of 
fibroblasts and epithelial cells increased over the first 4-8 h, 
The Journal of Cell Biology, Volume  111, 1990  736 Figure 5.  CAM cellular proliferation after 8 h TGFffl treatment as revealed by 3H-thymidine labeling  from 4 to 8 h. (A) CAMs treated 
with TGF/31 (50 ng) for 8 h demonstrated a central zone of decreased cellular labeling  with peripheral areas of increased labeling.  B and 
C represent areas shown at higher magnification  below. (B) High power magnification  of central zone of decreased cellular labeling.  (C) 
High power magnification of  peripheral areas of increased labeling.  (B) High power magnification  of control-treated CAM. Representative 
sections (10/zm) were processed for autoradiography as described in Materials  and Methods and stained with toluldine blue.Jb, Fibrohlasts; 
ae, allantoic epithelium.  Bars: (A) 200/tin;  (B, C, and D) 50/~m. 
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an unexpected sharp decrease in density. As described above, 
it was not until 16 h that increased numbers of small blood 
vessels and capillaries were observed in the CAM mesen- 
chyme. In concordance with this observation, the density of 
endothelial cells beneath the SEC did not begin to increase 
until 16 h, and it reached a peak density at 48 h, ',~2-fold 
higher than in controls. Since the SEC appeared to expand 
during the first 24 h of TGF~I treatment (compare Fig. 3, 
a, d, and f), our measurements probably underestimate the 
true increases in CAM endothelial cell density. Nevertheless, 
TGF/31-stimulated increases in endothelial cell density were 
delayed relative to the multiple effects of TGF~I on CAM 
fibroblasts and allantoic epithelial cells. 
Effect of TGF/31 on Cell Proliferation 
To  determine the contribution of cellular proliferation in 
TGF~l-stimulated density effects, 3H-thymidine was used to 
label  nuclei  of actively proliferating cells.  After  8  h  of 
TGF~I (50 ng) treatment, a zone of proliferative inhibition 
was  noted,  corresponding  to  the  area of TGFSl-induced 
fibroblast and epithelial accumulation (Fig. 5 a). Within this 
central zone of proliferative inhibition (Fig.  5 b),  the 3H- 
thymidine labeling of  both fibroblasts and allantoic epithelial 
cells was significantly diminished as compared to peripheral 
regions (Fig. 5 c) and control-treated CAMs (Fig. 5 d). Fur- 
thermore, note that the diminished cellular labeling in Fig. 
5 b does not take into account the increased fibroblast and 
allantoic epithelial cell densities observed after 8 h of'rGF~/1 
treatment (e.g., Figs. 3 b and 4). The proliferative rates of 
chorionic epithelial cells and endothelial cells within the 
SEC could not be assessed at 8 h since these cells could not 
be adequately differentiated from each other. 
The antiproliferative effect of TGF~I was sustained over 
24 h (Fig. 6 a). At this time, the total area of inhibition was 
only slightly expanded as compared to at 8 h, but the border 
of proliferative inhibition appeared to have sharpened (com- 
pare  Figs.  6  b  and 5  c).  Additionally, a  focus of highly 
proliferative basal chorionic epithelial cells was usually seen 
just peripheral to the central region of chorionic epithelial 
stratification (Fig. 6 b). 
TGF/~l-stimulated increases in endothelial cell density ap- 
peared to be mediated primarily through increased prolifera- 
tion. At 24 h of TGF~/1 (50 ng) treatment, two subsets of en- 
dothelial cells were distinguishable by their labeling indices. 
Endothelial cells within the SEC demonstrated a very low 
percentage of labeled nuclei (Fig. 6, b and c). Yet, the en- 
dothelial cells beneath the SEC, within radiating capillary 
cords and small blood vessels, demonstrated a high percent- 
age of labeled nuclei (Fig. 6 c). Note that as capillary cords 
approached the SEC, the nuclear labeling of  endothelial cells 
diminished (Fig. 6 c). At 24 h of TGF~I treatment, '~49 % 
of the endothelial cells within radiating capillaries and blood 
vessels were labeled, while in control-treated CAMs only 
17 % of these endothelial cells were labeled (P < 0.001, n = 
6, two-tailed t test). Since at this time endothelial cells be- 
neath the SEC reached a density "~2-fold higher than in con- 
trois and a proliferative rate '~3-fold higher than in controls; 
endothelial cell migration from more distant sites probably 
does not contribute significantly to the changes in endothe- 
lial cell density stimulated by TGF~I. 
Discussion 
Due to the seemingly disparate in vivo and in vitro effects 
of TGF~ on endothelial cells, we have examined the progres- 
sion of cellular responses that occur during TGF~l-induced 
angiogenesis with hope of gaining mechanistic insight. TGF/~I 
induced gross angiogenesis when delivered to the chicken 
CAM. This induction was apparent within 24 h of treatment, 
it was dose responsive, and it was qualitatively different from 
the angiogenesis induced by maximal doses of bFGE Histo- 
logic analysis revealed that TGF~I  induced rapid,  pleio- 
tropic cellular responses. At 4 h after TGF/31 treatment, both 
fibroblasts and epithelial cells accumulated in the central area 
of TGF~I delivery. This was apparently due to the migration 
of these ceils from peripheral areas since their proliferative 
rates were markedly reduced in the central area at 8 and 24 h. 
The rapidity of fibroblast and epithelial cell responses and 
their diminished magnitude with increasing distance from 
the methylcellulose disk suggest that TGF/~I diffuses rapidly 
into the CAM and establishes a concentration gradient of 
biologic activity. Although it was not determined whether 
the CAM fibroblast and epithelial cell responses were the re- 
sult of direct TGFI~I action, the direct effects of TGF~I on 
similar cells cultured in vitro support this hypothesis. In 
vitro experiments have demonstrated that TGF/~I inhibits the 
proliferation of most cell  types  (reviewed in  Moses  and 
Lyons, 1990). TGF~I stimulates fibroblast chemotaxis (Pos- 
tlethwaithe et al., 1987),  morphologic alteration (Shipley et 
al., 1984),  delayed cell cycle kinetics (Shipley et al., 1985; 
Sorrentino and Bandyopadhyay, 1989), and extracellular ma- 
trix production (Ignotz and Massague, 1986; Fine and Gold- 
stein, 1987). TGFI31 has also been shown to stimulate chemo- 
taxis of human keratinocytes (Nickoloff  et al., 1988). These 
examples of TGF~/1 effects in vitro are consistent with our 
in vivo observations. 
Previous studies involving in vivo TGF~ administration 
have not separated the effects of TGF~I on cellular migration 
and proliferation (Pierce et al.,  1989a,  b;  Roberts et al., 
1986;  Sprugel et al.,  1987).  The relative contributions of 
TGF/~l-stimulated cellular migration versus proliferation in 
achieving increased cellular density in vivo are unknown 
(Pierce et al.,  1988).  Our findings indicate that TGF~/1 in- 
duced CAM fibroblast and allantoic epithelial cell accumula- 
tion primarily through chemotaxis. Once these cells migrated 
into the central area of TGF/~I delivery their proliferation 
was inhibited. These observations are consistent with in vitro 
studies which demonstrated that TGF~I induces cellular che- 
motaxis at concentrations much lowerthan those required to 
elicit other responses, including growth inhibition (Postle- 
thwaithe et al., 1987; Wahl et al., 1987).  The question then 
arises as to the precise origin of the migrating cells and how 
their emigration from this location in response to TGF~I is 
compensated. Preliminary experiments suggest that the marked 
chemotaxis of fibroblasts and epithelial cells may be com- 
pensated by an annulus of highly proliferative cells surround- 
ing the area of cellular accumulation. Perhaps the induction 
of stimulatory factors by TGF/~I, such as PDGF (Leof  et al., 
1986; Soma and Grotendorst, 1989), would lead to concen- 
tration-dependent proliferative signals. In distal areas, where 
TGF~'I levels would be diminished, indirect stimulatory ef- 
fects might then predominate over the direct inhibitory effects 
of TGF~/1. 
The Journal of Cell Biology, Volume  111, 1990  738 Figure 6.  CAM cellular proliferation  after 24 h TGF/31 treatment  as revealed by 3H-thymidine labeling from 20 to 24 h.  (,4) The zone 
of proliferative  inhibition was sustained throughout  24 h.  B represents the area shown at higher magnification below. (B) High power 
magnification of  transitional area between zone of proliferative inhibition and peripheral areas. As compared to at 8 h, the border demarcat- 
ing these areas appeared to sharpen, and additionally, there was usually an adjacent focus of highly proliferative chorionic epithelial cells 
(ce). (C) Note that as capillary cords approached and connected with the SEC (sec) the endothelial cell labeling diminished. Representative 
sections (10/~m) were processed for autoradiography as described in Materials and Methods and stained with toluidine blue. ae, Allantoic 
epithelium.  Bars:  (A) 200 t~m; (B and C) 50/~m. 
In contrast to the rapid effects of TGFB1  on CAM fibro- 
blasts and epithelial cells, the effects of'l'GF~l on endothelial 
cells  were  delayed.  Initially,  the  endothelial  cell  density 
declined,  perhaps as a  result of the rapid accumulation of 
fibroblast and epithelial cells.  Increases in endothelial cell 
density  were  first observed  16  h  after  TGFB1  treatment, 
whereas fibroblast and epithelial cell densities increased by 
4 h. Capillary cords developed in a radial pattern relative to 
the point of TGFfll delivery, and they were often incomplete 
in their connection to the SEC.  These observations suggest 
that radial capillary cords originated from larger blood ves- 
sels  and  extended  primarily  through  growth  towards  the 
SEC. It has been demonstrated that the growth and extension 
of capillaries takes place by the combined migration of en- 
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dothelial  cells  behind  the  tip  (Ausprunk  and  Folkman, 
1977). This spatial pattern of endothelial cell proliferation 
was also observed during TGF~-induced angiogenesis since 
the  percentage  of 3H-thymidine-labeled  endothelial  cells 
within radiating capillafi'ees and blood vessels was higher in 
distal  areas  as  compared  to proximal  areas.  As capillary 
cords approached and incorporated into the SEC, the prolif- 
eration of endothelial cells within these vessels was inhibited. 
The  observation  that  endothelial  cells  in  central  areas 
changed from a highly proliferative state, lining angiogenic 
capillary cords, to a quiescent state, lining the SEC, is consis- 
tent with in vitro data demonstrating that TGF/~I is directly 
inhibitory to the processes required to initiate angiogenesis 
(i.e., invasion, migration, proliferation) and directly stimu- 
latory to the processes required to resolve angiogenesis (i.e., 
capillary morphogenesis). The increased endothelial cell pro- 
liferation in peripheral  regions  is difficult to explain how- 
ever. At low concentrations, TGF/$1 could directly stimulate 
endothelial cell proliferation, but concentrations as low as 10 
pg/ml are reportedly inhibitory to proliferation in vitro (Baird 
and Durkin,  1986; Frater-Schroder et al.,  1986). A mecha- 
nism of indirect stimulation, via production of an autocrine 
stimulatory factor by endothelial cells is also possible, and 
in fact TGF/$1 has been shown to induce increased bFGF 
production in bovine corneal  endothelial cells (Plouet and 
Gospodarowicz,  1989). Finally, TGF/$1 could induce endo- 
thelial cell proliferation at low concentrations by stimulating 
production of a paracrine stimulatory factor from an inter- 
mediate cell type. Since angiogenic capillary cords were ob- 
served to grow through regions of previous fibroblast accum- 
ulation and extracellular matrix deposition, it is possible that 
fibroblasts contribute an active role in TGF~-induced anglo- 
genesis. 
Although macrophages clearly have an important role in 
wound healing  (Leibovich and  Ross,  1975;  Danon  et al., 
1989) and its associated angiogenesis (Polverini et al., 1977; 
Koch et al.,  1986), we did not find an association between 
endothelial cell growth and the presence of macrophages or 
PMNs. Previous work has suggested that wound-healing an- 
giogenesis can occur without inflammation (Eliason,  1978; 
Sholley et al.,  1978). It has been hypothesized that wound- 
healing angiogenesis is initiated without inflammation,  but 
amplified maximally through further secretion of angiogenic 
substances by macrophages (Eliason, 1978). This hypothesis 
is in agreement with our observations of TGF/$1-induced  an- 
giogenesis, which appeared to be initiated at the microvascular 
level in an inflammation-independent manner and remodeled 
into larger vessels in association with mononuclear inflam- 
mation. 
Several  recent findings  suggest the broader  significance 
of TGFBl-induced cellular accumulation and angiogenesis. 
Both TGF~I and TGF/T2 are developmentally expressed in 
tissues where angiogenesis occurs within organizing mesen- 
chyme.  In embryonic mouse limbs,  TGF~I  immunohisto- 
chemical staining is most profound in the developing mesen- 
chyme surrounding the marginal blood sinuses (Heine et al., 
1987). In embryonic mouse skin, both TGF~ immunohisto- 
chemical staining  (Heine et al.,  1987) and TGF/~2 mRNA 
(Pelton et al.,  1989) are localized in the subepidermal mes- 
enchyme during periods of increased capillary growth and 
extracellular matrix organization.  The capacity of tumors to 
induce the production of angiogenic factors in normal tissues 
has also been suggested (Folkman,  1984). Many tumor cell 
lines that produce and secrete TGF/~I are also highly desmo- 
plastic and angiogenic in vivo (Bergh,  1988; Beauchamp et 
al., 1990). Thus, the capacity of TGF/~I to initiate a program 
of cellular responses which ultimately results in connective 
tissue remodeling and angiogenesis may be a conserved pro- 
cess utilized in embryogenesis, recapitulated in wound heal- 
ing,  and exploited in tumor progression. 
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